belinostat belinostat belinostat (trade name beleodaq, previously known as pxd101) is a histone deacetylase inhibitor drug developed by topotarget for the treatment of hematological malignancies and solid tumors. belinostatclinical datatrade namesbeleodaqother namespxd101ahfs/drugs.combeleodaqroutes ofadministrationintravenous (iv)atc codel01xh04 (who) legal statuslegal status us: ℞-only pharmacokinetic databioavailability100% (iv)protein binding92.9–95.8%metabolismugt1a1excretionurineidentifiers iupac name (2e)-n-hydroxy-3-prop-2-enamide cas number866323-14-0 npubchem cid6918638chemspider5293831 yuniif4h96p17nzkeggd08870chebichebi:61076 ychemblchembl408513 ycomptox dashboard (epa)dtxsid60194378 chemical and physical dataformulac15h14n2o4smolar mass318.35 g·mol−13d model (jsmol)interactive image smiles o=s(=o)(nc1ccccc1)c2cc(\c=c\c(=o)no)ccc2 inchi inchi=1s/c15h14n2o4s/c18-15(16-19)10-9-12-5-4-8-14(11-12)22(20,21)17-13-6-2-1-3-7-13/h1-11,17,19h,(h,16,18)/b10-9+ ykey:ncnrhfgmjrprsk-mdzdmxlpsa-n y it was approved in july 2014 by the us fda to treat peripheral t-cell lymphoma. in 2007 preliminary results were released from the phase ii clinical trial of intravenous belinostat in combination with carboplatin and paclitaxel for relapsed ovarian cancer. final results in late 2009 of a phase ii trial for t-cell lymphoma were encouraging. belinostat has been granted orphan drug and fast track designation by the fda, and was approved in the us for the use against peripheral t-cell lymphoma on 3 july 2014. it is not approved in europe as of august 2014. the approved pharmaceutical formulation is given intravenously.: 180 belinostat is primarily metabolized by ugt1a1; the initial dose should be reduced if the recipient is known to be homozygous for the ugt1a1*28 allele.: 179 and 181